Specific LPA receptor subtype mediation of LPA-induced hypertrophy of cardiac myocytes and involvement of Akt and NFκB signal pathways

Journal of Cellular Biochemistry

Volumn 103, Issue 6, 2008, Pages 1718-1731

  Chen, Jinghai ^a   Chen, Yuefeng ^a   Zhu, Weiquan ^a   Han, Yu ^a   Han, Bianmei ^a   Xu, Ruixia ^a   Deng, Linzi ^a   Cai, Yan ^a   Cong, Xiangfeng ^a   Yang, Yuejing ^a   Hu, Shengshou ^a   Chen, Xi ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Hypertrophy; Lysophosphatidic acid; Myocardial infarction; Receptor; Signaling pathway

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUCINE; LUCIFERASE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; MESSENGER RNA; PROTEIN KINASE B; PYRROLIDINE DITHIOCARBAMATE; RAPAMYCIN; SN 50; TRANSCRIPTION FACTOR RELA; WORTMANNIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ENZYME ACTIVATION; FEMALE; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; ANIMALS, NEWBORN; CELL SURVIVAL; CELLS, CULTURED; DIPHOSPHATES; ENZYME INHIBITORS; FEMALE; GLYCEROL; HYPERTROPHY; LYSOPHOSPHOLIPIDS; MAP KINASE SIGNALING SYSTEM; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; NF-KAPPA B; PHOSPHATIDIC ACIDS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LYSOPHOSPHATIDIC ACID; SIGNAL TRANSDUCTION; THIOPHOSPHORIC ACID ESTERS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

RATTUS;

EID: 41849107561     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21564     Document Type: Article

References (41)

1. Anliker B, Chun J. 2004. Cell surface receptors in lysophospholipid signaling. Semin Cell Dev Biol 15:457-465.
2. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O. 2006. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A 103:9643-9648.
3. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. 1995. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377:441-446.
4. Chen X, Cui Z, Zhang F, Chang W, Chen L, Liu L. 2002. Angiotensin II and cAMP regulate AT(1)-mRNA expression in rat cardiomyocytes by transcriptional mechanism. Eur J Pharmacol 448:1-9.
5. Chen X, Yang XY, Wang ND, Ding C, Yang YJ, You ZJ, Su Q, Chen JH. 2003. Serum lysophosphatidic acid concentrations measured by dot immunogold filtration assay in patients with acute myocardial infarction. Scand J Clin Lab Invest 63:497-503.
6. Chen J, Han Y, Zhu W, Ma R, Han B, Cong X, Hu S, Chen X. 2006. Specific receptor subtype mediation of LPA-induced dual effects in cardiac fibroblasts. FEBS Lett 580:4737-4745.
7. Contos JJ, Ishii I, Chun J. 2000. Lysophosphatidic acid receptors. Mol Pharmacol 58:1188-1196.
8. Cook SA, Novikov MS, Ahn Y, Matsui T, Rosenzweig A. 2003. A20 is dynamically regulated in the heart and inhibits the hypertrophic response. Circulation 108:664-667.
9. Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A. 1997. Signal characteristics of G protein-transactivated EGF receptor. Embo J 16:7032-7044.
10. Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J, Mills GB. 2002. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 1582:257-264.
11. Fischer DJ, Nusser N, Virag T, Yokoyama K, Wang D, Baker DL, Bautista D, Parrill AL, Tigyi G. 2001. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol 60:776-784.
12. Fukushima N, Chun J. 2001. The LPA receptors. Prostaglandins Other Lipid Mediat 64:21-32.
13. Funakoshi-Tago M, Sonoda Y, Tanaka S, Hashimoto K, Tago K, Tominaga S, Kasahara T. 2003. Tumor necrosis factor-induced nuclear factor kappaB activation is impaired in focal adhesion kinase-deficient fibroblasts. J Biol Chem 278:29359-29365.
14. Goetzl EJ, Lee H, Azuma T, Stossel TP, Turck CW, Karliner JS. 2000. Gelsolin binding and cellular presentation of lysophosphatidic acid. J Biol Chem 275:14573-14578.
15. Gupta S, Purcell NH, Lin A, Sen S. 2002. Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy. J Cell Biol 159:1019-1028.
16. Hasegawa Y, Erickson JR, Goddard GJ, Yu S, Liu S, Cheng KW, Eder A, Bandoh K, Aoki J, Jarosz R, Schrier AD, Lynch KR, Mills GB, Fang X. 2003. Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J Biol Chem 278:11962-11969.
17. Hattori Y, Nakanishi N, Kasai K. 1997. Role of nuclear factor kappa B in cytokine-induced nitric oxide and tetrahydrobiopterin synthesis in rat neonatal cardiac myocytes. J Mol Cell Cardiol 29:1585-1592.
18. Hilal-Dandan R, Means CK, Gustafsson AB, Morissette MR, Adams JW, Brunton LL, Heller Brown J. 2004. Lysophosphatidic acid induces hypertrophy of neonatal cardiac myocytes via activation of Gi and Rho. J Mol Cell Cardiol 36:481-493.
19. Karliner JS, Honbo N, Summers K, Gray MO, Goetzl EJ. 2001. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol 33:1713-1717.
20. Kitayama J, Shida D, Sako A, Ishikawa M, Hama K, Aoki J, Arai H, Nagawa H. 2004. Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res 6:R640-R646.
21. Li Y, Ha T, Gao X, Kelley J, Williams DL, Browder IW, Kao RL, Li C. 2004. NF-kappaB activation is required for the development of cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol 287:H1712-H1720.
22. Li HL, Wang AB, Huang Y, Liu DP, Wei C, Williams GM, Zhang CN, Liu G, Liu YQ, Hao DL, Hui RT, Lin M, Liang CC. 2005. Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. Free Radic Biol Med 38:243-257.
23. Matsui T, Nagoshi T, Rosenzweig A. 2003. Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle 2:220-223.
24. Mills GB, Moolenaar WH. 2003. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3:582-591.
25. Moolenaar WH. 1999. Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res 253:230-238.
26. Okusa MD, Ye H, Huang L, Sigismund L, Macdonald T, Lynch KR. 2003. Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 285:F565-F574.
27. Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, Lin A. 2001. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci U S A 98:6668-6673.
28. Romashkova JA, Makarov SS. 1999. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401:86-90.
29. Rother E, Brandi R, Baker DL, Goyal P, Gebhard H, Tigyi G, Siess W. 2003. Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 108:741-747.
30. Schulte KM, Beyer A, Kohrer K, Oberhauser S, Roher HD. 2001. Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: Over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer. Int J Cancer 92:249-256.
31. Shida D, Watanabe T, Aoki J, Hama K, Kitayama J, Sonoda H, Kishi Y, Yamaguchi H, Sasaki S, Sako A, Konishi T, Arai H, Nagawa H. 2004. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab Invest 84:1352-1362.
32. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, Franke TF, Cantley LC, Izumo S. 2002. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 22:2799-2809.
33. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ, Izumo S. 2003. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107:1664-1670.
34. Tigyi G, Parrill AL. 2003. Molecular mechanisms of lysophosphatidic acid action. Prog Lipid Res 42:498-526.
35. Virag T, Elrod DB, Liliom K, Sardar VM, Parrill AL, Yokoyama K, Durgam G, Deng W, Miller DD, Tigyi G. 2003. Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol 63:1032-1042.
36. Wang Y, Chen X, Zhu W, Zhang H, Hu S, Cong X. 2006. Growth inhibition of mesenchymal stem cells by aspirin: involvement of the WNT/beta-catenin signal pathway. Clin Exp Pharmacol Physiol 33:696-701.
37. Xu YJ, Ouk Kim S, Liao DF, Katz S, Pelech SL. 2000. Stimulation of 90- and 70-kDa ribosomal protein S6 kinases by arginine vasopressin and lysophosphatidic acid in rat cardiomyocytes. Biochem Pharmacol 59:1163-1171.
38. Yamada T, Sato K, Komachi M, Malchinkhuu E, Tobo M, Kimura T, Kuwabara A, Yanagita Y, Ikeya T, Tanahashi Y, Ogawa T, Ohwada S, Morishita Y, Ohta H, Im DS, Tamoto K, Tomura H, Okajima F. 2004. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through L PA1. J Biol Chem 279:6595-6605.
39. Yang YJ, Tang YD, Ruan YM, Zhang P, Zhou YW, Wang PH, Gao RL, Chen JL, Chen ZJ. 2003. Comparative effects of Carvedilol and losartan alone and in combination for preventing left ventricular remodeling after acute myocardial infarction in rats. Circ J 67:159-162.
40. Yoshida K, Nishida W, Hayashi K, Ohkawa Y, Ogawa A, Aoki J, Arai H, Sobue K. 2003. Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. Circulation 108:1746-1752.
41. Yue TL, Gu JL, Wang C, Reith AD, Lee JC, Mirabile RC, Kreutz R, Wang Y, Maleeff B, Parsons AA, Ohlstein EH. 2000. Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem 275:37895-37901.